<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02779192</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-1005-203</org_study_id>
    <nct_id>NCT02779192</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss</brief_title>
  <acronym>PANIHL</acronym>
  <official_title>A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Pharmaceuticals, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sound Pharmaceuticals, Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPI-1005 is a novel oral drug that contains a glutathione peroxidase mimetic (ebselen) that&#xD;
      will be tested in subjects with a history of NIHL at risk for additional NIHL. The goal of&#xD;
      this multi-center Phase 2b study is to determine whether SPI-1005 is effective in reducing an&#xD;
      acute NIHL in this affected population. In this Phase 2b study subjects with prior NIHL will&#xD;
      be enrolled and exposed to a calibrated sound challenge (CSC) that induces a slight acute&#xD;
      NIHL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled, safety and efficacy study of oral SPI-1005 in&#xD;
      adults with Noise Induced Hearing Loss (NIHL). All recruited subjects will have their&#xD;
      severity of NIHL determined before the start of SPI-1005 treatment using various hearing&#xD;
      tests. Subjects will be enrolled and randomized to either placebo or SPI-1005. Subjects will&#xD;
      be dosed with either placebo or SPI-1005 for 7 days, beginning 1 day before an acute NIHL.&#xD;
      Subjects will have hearing tests performed before and immediately after a calibrated sound&#xD;
      challenge (CSC). Follow-up hearing tests will be performed post-CSC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the Incidence of a Significant Threshold Shift</measure>
    <time_frame>Within 1 day</time_frame>
    <description>Post Controlled Sound Challenge pure tone audiometry will be compared with baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in word recognition score</measure>
    <time_frame>Within 1 day</time_frame>
    <description>Post Controlled Sound Challenge Words in Noise Test score will be compared with baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Within 7 days</time_frame>
    <description>Adverse events due to study drug will be compared with placebo</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Noise Induced Hearing Loss</condition>
  <arm_group>
    <arm_group_label>SPI-1005 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg SPI-1005, capsule, bid, po, x7d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg SPI-1005, capsule, bid, po, x7d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mg SPI-1005, capsule, bid, po, x7d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 200mg</intervention_name>
    <description>Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days</description>
    <arm_group_label>SPI-1005 200 mg</arm_group_label>
    <other_name>Low Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 400mg</intervention_name>
    <description>Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days</description>
    <arm_group_label>SPI-1005 400 mg</arm_group_label>
    <other_name>High Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or female patients, 18-50 years of age&#xD;
&#xD;
          -  History of either recreational and/or occupational exposure to noise&#xD;
&#xD;
          -  Voluntarily consent to participate in the study&#xD;
&#xD;
          -  Females of childbearing potential should be using and committed to continue using one&#xD;
             of the following acceptable birth control methods: Sexual abstinence (inactivity) for&#xD;
             14 days prior to screening through study completion; or intra-uterine device in place&#xD;
             for at least 3 months prior to study through study completion; or barrier method&#xD;
             (condom or diaphragm) with spermicide for at least 14 days prior to screening through&#xD;
             study completion; or stable hormonal contraceptive for at least 3 months prior to&#xD;
             study through study completion; or surgical sterilization (vasectomy) of partner at&#xD;
             least 6 months prior to study.&#xD;
&#xD;
          -  Females of non-childbearing potential should be surgically sterile (bilateral tubal&#xD;
             ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral&#xD;
             oophorectomy at least 2 months prior to study) or be at least 3 years since last&#xD;
             menses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use or within 60 days prior to study of excluded ototoxic medications&#xD;
&#xD;
          -  History of autoimmune inner ear disease&#xD;
&#xD;
          -  History of middle ear or inner ear surgery&#xD;
&#xD;
          -  Current conductive hearing loss or middle ear effusion&#xD;
&#xD;
          -  Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal,&#xD;
             endocrine, immunologic, or psychiatric disease&#xD;
&#xD;
          -  History of hypersensitivity or idiosyncratic reaction to compounds related to ebselen&#xD;
&#xD;
          -  Current use or within 30 days prior to study of drugs or substances known to be strong&#xD;
             inhibitors or inducers of cytochrome P450 enzymes&#xD;
&#xD;
          -  Participation in another investigational drug or device study within 90 days prior to&#xD;
             study enrollment&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kil, MD</last_name>
    <role>Study Chair</role>
    <affiliation>SOUND PHARMACEUTICALS, INC.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Kil, MD</last_name>
    <phone>2066342559</phone>
    <email>jkil@soundpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Hoffer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hinrich Staecker, MD/PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MUSC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joe Kutz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sound Pharmaceuticals, Inc.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Noise Induced Hearing Loss</keyword>
  <keyword>Prevent Acute Noise Induced Hearing Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Noise-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

